Cargando…

Adjuvant Bidirectional Chemotherapy with Intraperitoneal Pemetrexed Combined with Intravenous Cisplatin for Diffuse Malignant Peritoneal Mesothelioma

Cytoreductive surgery (CRS) with heated intraoperative intraperitoneal chemotherapy (HIPEC) has emerged as optimal treatment for diffuse malignant peritoneal mesothelioma (DMPM) showing median survivals of 36–92 months. However, recurrences occur frequently even in patients undergoing optimal cytred...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bijelic, Lana, Stuart, O. Anthony, Sugarbaker, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423889/ https://www.ncbi.nlm.nih.gov/pubmed/22927839 http://dx.doi.org/10.1155/2012/890450

Ejemplares similares

Adjuvant Bidirectional Chemotherapy Using an Intraperitoneal Port
por: Sugarbaker, Paul H., et al.
Publicado: (2012)

Randomized trial of intravenous versus bidirectional chemotherapy after cytoreductive surgery for malignant peritoneal mesothelioma
por: Sugarbaker, Paul H.
Publicado: (2023)

Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients
por: Bijelic, Lana, et al.
Publicado: (2012)

Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy
por: Yan, Tristan D, et al.
Publicado: (2006)

Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer: Rationale and Report of Early Data
por: Sugarbaker, Paul H., et al.
Publicado: (2011)

Significant Clinical Benefit of Pemetrexed-based Chemotherapy for Advanced Diffuse Malignant Peritoneal Mesothelioma: A Case Presentation
por: Peitl, Milena, et al.
Publicado: (2017)

Bidirectional chemotherapy allowing surgery and HIPEC for malignant peritoneal mesothelioma
por: Noiret, Barbara, et al.
Publicado: (2019)

Bidirectional Intraoperative Chemotherapy Using Cisplatin and Ifosfamide for Intraperitoneal Mesothelioma in Severe Renal Impairment: A Case Report
por: Almesned, Razan K., et al.
Publicado: (2023)

Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma
por: Giger-Pabst, Urs, et al.
Publicado: (2018)

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
por: Goudar, Ranjit K
Publicado: (2008)

Systemic complications of the bidirectional intraoperative chemotherapy with intravenous ifosfamide and hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin plus doxorubicin
por: Hakeam, Hakeam, et al.
Publicado: (2019)

Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice.
por: Kondo, A., et al.
Publicado: (1996)

Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy
por: White, Michael G., et al.
Publicado: (2020)

Unusual radiologic presentations of malignant peritoneal mesothelioma
por: Sugarbaker, Paul Hendrick, et al.
Publicado: (2020)

A Case Report of Primary Pericardial Malignant Mesothelioma Treated with Pemetrexed and Cisplatin
por: Kim, Jung Sun, et al.
Publicado: (2017)

Gastrointestinal Complications in 147 Consecutive Patients with Peritoneal Surface Malignancy Treated by Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy
por: Casado-Adam, Angela, et al.
Publicado: (2011)

Comment on “Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy”
por: Yang, Haitang, et al.
Publicado: (2020)

Outcomes of multicystic peritoneal mesothelioma treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
por: Zahid, A, et al.
Publicado: (2020)

Bidirectional treatment of peritoneal metastasis with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and systemic chemotherapy: a systematic review
por: Ploug, Magnus, et al.
Publicado: (2020)

Quantitative X-ray Computed Tomography Peritoneography in Malignant Peritoneal Mesothelioma Patients Receiving Intraperitoneal Chemotherapy
por: Leinwand, Joshua C., et al.
Publicado: (2013)

Response to Comment on “Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy”
por: White, Michael G., et al.
Publicado: (2020)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Miyamoto, Yosuke, et al.
Publicado: (2021)

In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes
por: Papazoglou, Eleftherios D., et al.
Publicado: (2019)

Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy
por: Oien, Derek B., et al.
Publicado: (2018)

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations
por: Enomoto, Laura M, et al.
Publicado: (2019)

Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy
por: Hue, Hyejeong, et al.
Publicado: (2019)

Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial
por: Dietz, Michelle V, et al.
Publicado: (2023)

Effects of Neoadjuvant Intraperitoneal/Systemic Chemotherapy (Bidirectional Chemotherapy) for the Treatment of Patients with Peritoneal Metastasis from Gastric Cancer
por: Yonemura, Yutaka, et al.
Publicado: (2012)

Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies
por: Guchelaar, Niels A. D., et al.
Publicado: (2023)

Diffuse malignant peritoneal mesothelioma: A review
por: Sun, Luanbiao, et al.
Publicado: (2023)

Malignant peritoneal mesothelioma presenting as a mass in a Spigelian hernia. Report of a case
por: Sugarbaker, Paul H.
Publicado: (2020)

Systemic Chemotherapy prior to Cytoreductive Surgery and HIPEC for Carcinomatosis from Appendix Cancer: Impact on Perioperative Outcomes and Short-Term Survival
por: Bijelic, Lana, et al.
Publicado: (2012)

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
por: Nakano, Takashi, et al.
Publicado: (2020)

Long-Term Survival of More than 5 Years with Maintenance Therapy Using Single-Agent Pemetrexed in a Patient with Diffuse Malignant Peritoneal Mesothelioma
por: Otsuka, Yasuo, et al.
Publicado: (2023)

Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: a case report
por: Fasola, Gianpiero, et al.
Publicado: (2006)

Bidirectional chemotherapy combining intraperitoneal docetaxel with intravenous 5-fluorouracil and oxaliplatin for patients with unresectable peritoneal metastasis from gastric cancer: the first study in Western countries
por: Lo Dico, Rea, et al.
Publicado: (2020)

Interferon-β Produces Synergistic Combinatory Anti-Tumor Effects with Cisplatin or Pemetrexed on Mesothelioma Cells
por: Li, Quanhai, et al.
Publicado: (2013)

Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma
por: Gesmundo, Iacopo, et al.
Publicado: (2022)

Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy
por: Eoh, Kyung Jin, et al.
Publicado: (2017)

Benefit of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy and Bidirectional Chemotherapy for Patients with Gastric Cancer with Peritoneal Carcinomatosis Considering Cytoreductive Surgery
por: Yu, Hsin-Hsien, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sbvgaegc8eluo0c1ljpnubllge